Significant progress in stem cell research taking place in India

14 September 2015

Stem cell research carried out in India is saving lives and is proving to be a boon for patients. Though the country has only nine major organization at present engaged in stem cell research, the field of regenerative medicine and stem cell biology is gaining ground, reports The Pharma Letter’s India correspondent.

With the stem cell market in India estimated to touch $600 million by 2017, the government is focusing on a strategy to leverage intellectual talent and become a global leader in stem cells research and therapy.

Currently in the midst of strengthening the regulatory environment, sources say the Indian government aims to form robust guidelines for stem cell therapy in the country, which also includes fiscal incentives for companies engaged in product development.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >